Post Profile






Study Unlocks How Changes in Gene Activity Early During Therapy Can Establish the Roots of Drug-Resistant Melanoma

A UCLA-led study of changes in gene activity in BRAF-mutated melanoma suggests these epigenomic alterations are not random but can explain how tumors are already developing resistance as they shrink in response to treatment with a powerful class of drugs called MAP kinase (MAPK)-targeted inhibitors.
read more

share

Related Posts


Identifying Mechanism Behind Treatment Resistance In Melanoma Suggests Possible Strategy For Improvement

Health : Medical News Today

A multi-institutional study has revealed that BRAF-positive metastatic malignant melanomas develop resistance to treatment with drugs targeting the BRAF/MEK growth pathway through a major change in metabolism. The findings, which wi...

New Research Unlocks How Melanoma Can Resist Newly Approved Drug Combo Therapy

Health : Newswise Medical News

In a new study researchers at the UCLA Jonsson Comprehensive Cancer Center have uncovered how melanoma becomes resistant to a promising new drug combo therapy utilizing BRAF+MEK inhibitors in patients after an initial period of tumo...

UCLA Cancer Researchers Uncover Drug Resistance Mechanisms In The Most Common Form Of Melanoma

Health : Medical News Today

Researchers with UCLA's Jonsson Comprehensive Cancer Center have found that melanoma patients whose cancers are caused by mutation of the BRAF gene become resistant to a promising targeted treatment through another genetic mutation ...

Cancer Researchers Translate New Laboratory Findings to Enhance Melanoma Treatment

Health : Newswise Medical News

Drugs called BRAF inhibitors shrink most melanoma tumors quickly. Despite good responses, melanoma tumors do not shrink away completely. Left-behind cancer cells allow tumors to grow back drug resistant. Using Multiple drugs that...

Insight into melanoma drug resistance pathways identifies potential new treatment option

Health : Medical News Today

Although most of the melanomas that harbor BRAF mutations respond dramatically to treatment with BRAF inhibitors, nearly all develop resistance to the drugs in less than a year, and previous studies showed that melanomas alter a cel...

Comments


Copyright © 2016 Regator, LLC